NASDAQ: RDHL - RedHill Biopharma Ltd.

Altı ay boyunca karlılık: +1 692.04%
Sektör: Healthcare

Promosyon programı RedHill Biopharma Ltd.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Daha fazla ayrıntı
Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

ISIN US7574681034
Цена ао 0.4797
Выручка 0.0063
EBITDA -0.0407
P/S 28.04
P/BV 2.94
EV/EBITDA -3.72
Число акций ао 0.00648 млрд
Сайт https://www.redhillbio.com
P/E 0.4036
Валюта usd
IPO date 2013-01-07
Sector Health Care
Industry Pharmaceuticals
Валюта отчета usd
Günlük fiyat değişimi: 0% (8.1)
Haftalık fiyat değişimi: +0.3717% (8.07)
Aylık fiyat değişimi: -26.43% (11.01)
3 ayda fiyat değişimi: +2 085.64% (0.3706)
Altı ayda fiyat değişimi: +1 692.04% (0.452)
Yıllık fiyat değişimi: +1 370.05% (0.551)
3 yılda fiyat değişimi: +72.71% (4.69)
5 yılda fiyat değişimi: +5.61% (7.67)
Yılbaşından bu yana fiyat değişimi: +2 317.91% (0.335)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 36.55 1
P/BV 115.06 1
P/E 9.95 9
EV/EBITDA -7.93 0
Toplam: 5.38

Yeterlik

İsim Anlam Seviye
ROA, % 103.77 10
ROE, % 1155.91 10
Toplam: 5

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0399 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 3.38 1
karlılık Ebitda, % -27.85 0
karlılık EPS, % -106.74 0
Toplam: 0.2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Gagnon Securities, LLC 89589 10.16
JANE STREET GROUP, LLC 86812 9.85
Rhumbline Advisers 34847 3.95
We Are One Seven, LLC 15750 1.79
Squarepoint Ops LLC 10947 1.24
Group One Trading, L.P. 615 0.07
Morgan Stanley 576 0.07
Aspire Private Capital, LLC 405 0.05
Royal Bank of Canada 142 0.02
Steward Partners Investment Advisory, LLC 125 0.01



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Dror Ben-Asher Co-Founder, Chairman & CEO 594.61k 1966 (58 yıllar)
Mr. Gilead Raday MPhil, MSc Chief Operating Officer 365.56k 1975 (49 yıllar)
Mr. Adi Frish Chief Corporate & Business Development Officer 339.3k 1970 (54 yıl)
Mr. Rick D. Scruggs Chief Commercial Officer, President of RedHill Biopharma Inc. & Director 469.8k 1960 (64 yıl)
Mr. Razi Ingber Chief Financial Officer 339.82k 1984 (40 yıllar)
Ms. Alexandra Okmian Senior Business Development & Investor Relations Manager N/A
Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development 299.29k 1955 (69 yıllar)
Ms. Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs N/A
Mr. Guy Goldberg J.D. Chief Business Officer 338.13k 1976 (48 yıllar)

Adres: Israel, Tel Aviv, 21 Ha’arba’a Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.redhillbio.com